Search Results - "Maas Enriquez, M"

Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial by Saxena, K., Lalezari, S., Oldenburg, J., Tseneklidou-Stoeter, D., Beckmann, H., Yoon, M., Maas Enriquez, M.

“…Introduction BAY 81‐8973 (Kovaltry®) is a full‐length, unmodified recombinant human factor VIII (FVIII) with the same amino acid sequence as sucrose‐formulated…”
Get full text

Population pharmacokinetic characterization of BAY 81‐8973, a full‐length recombinant factor VIII: lessons learned ‒ importance of including samples with factor VIII levels below the quantitation limit by Garmann, D., McLeay, S., Shah, A., Vis, P., Maas Enriquez, M., Ploeger, B.A.

“…Introduction The pharmacokinetics (PK), safety and efficacy of BAY 81‐8973, a full‐length, unmodified, recombinant human factor VIII (FVIII), were evaluated in…”
Get full text

Prophylaxis vs. on‐demand treatment with BAY 81‐8973, a full‐length plasma protein‐free recombinant factor VIII product: results from a randomized trial (LEOPOLD II) by Kavakli, K., Yang, R., Rusen, L., Beckmann, H., Tseneklidou‐Stoeter, D., Maas Enriquez, M., Yang, Renchi, Zhao, Yongqiang, Sun, Jing, Wang, Xuefeng, Wu, Depei, Hlusi, Antonin, Fukutake, Katsuyuki, Hanabusa, Hideji, Fujii, Teruhisa, Ramírez, Oscar Pérez, Alvarado, Blanca Salazar, Serban, Margit, Rusen, Luminita, Uscatescu, Valentina, Truica, Cristina, Kostic, Gordana, Konstantinidis, Nada, Igrutinovic, Zoran, Perina, Farida, Andreeva, Tatiana, Kavakli, Kaan, Antmen, Bulent, Sasmaz, Ilgen, Kupesiz, Alphan, Yesilipek, Mehmet Akif, Peng, Ching‐Tien, French, James, Escobar, Miguel, Mahlangu, Johnny, Pool, Roger

“…Summary Background BAY 81‐8973 is a new full‐length human recombinant factor VIII product manufactured with technologies to improve consistency in…”
Get full text

BAY 81-8973, a full-length recombinant factor VIII: results from an International comparative laboratory field study by Kitchen, S., Beckmann, H., Katterle, Y., Bruns, S., Tseneklidou-Stoeter, D., Maas Enriquez, M.

“…Introduction BAY 81‐8973 is a full‐length, unmodified, recombinant human factor VIII (FVIII) with the same primary amino acid sequence as sucrose‐formulated…”
Get full text

BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial by Ljung, R., Kenet, G., Mancuso, M. E., Kaleva, V., Rusen, L., Tseneklidou-Stoeter, D., Michaels, L. A., Shah, A., Hong, W., Maas Enriquez, M.

“…Introduction BAY 81‐8973, a full‐length, unmodified, recombinant factor VIII (FVIII) in development for treatment of haemophilia A, has the same primary amino…”
Get full text

Chromogenic assay for BAY 81‐8973 potency assignment has no impact on clinical outcome or monitoring in patient samples by Kitchen, S., Katterle, Y., Beckmann, H., Maas Enriquez, M.

“…Essentials Discrepancies can exist in factor VIII activity measured by the one‐stage or chromogenic assays. LEOPOLD trial data were used to assess clinical…”
Get full text

Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme by Oldenburg, J., Windyga, J., Hampton, K., Lalezari, S., Tseneklidou-Stoeter, D., Beckmann, H., Maas Enriquez, M.

“…Introduction BAY 81‐8973 is a recombinant factor VIII (rFVIII) with the same amino acid sequence as Bayer's sucrose‐formulated rFVIII (rFVIII‐FS) but…”
Get full text

Efficacy and safety evaluation of sucrose-formulated recombinant factor VIII for Taiwanese patients with haemophilia A by YOUNG, J.-H., LIU, H.-C., HSUEH, E.-J., HUANG, M.-L., PENG, C.-T., CHEN, R.-L., MAAS-ENRIQUEZ, M., ACHILLES, K.

Get full text

MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS) by Fazekas, F, Sørensen, P S, Filippi, M, Ropele, S, Lin, X, Koelmel, H W, Fernandez, O, Pozzilli, C, O'Connor, P, Enriquez, M Maas, Hommes, O R

“…Background: Monthly application of high-dose intravenous immunoglobulin (IVIG) to patients with secondary progressive multiple sclerosis (MS) showed no…”
Get full text

Intravenous immunoglobulin in relapsing-remitting multiple sclerosis : A dose-finding trial by FAZEKAS, F, LUBLIN, F. D, LI, D, FREEDMAN, M. S, HARTUNG, H. P, RIECKMANN, P, SOELBERG SØRENSEN, P, MAAS-ENRIQUEZ, M, SOMMERAUER, B, HANNA, K

“…Several studies have reported a reduction of relapses after the long-term administration of IV immunoglobulin (IVIG) to patients with relapsing-remitting…”
Get full text

Peripheral deposition of α1-protease inhibitor using commercial inhalation devices by BRAND, P, BECKMANN, H, MAAS ENRIQUEZ, M, MEYER, T, MÜLLINGER, B, SOMMERER, K, WEBER, N, WEUTHEN, T, SCHEUCH, G

Get full text

Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis - results of a retrospective multicenter observational study over five years by Haas, J, Maas-Enriquez, M, Hartung, H P

“…Use of intravenous immunoglobulins (IVIG) has been recommended for treatment of RRMS if first line therapy with beta-interferon or glatiramer acetate is not…”
Get full text

ESIMS--an ongoing clinical trial in secondary progressive multiple sclerosis by Hommes, O R, Maas-Enriquez, M

“…The design of a double-blind, placebo-controlled, European-Canadian Study on IVIG treatment in multiple sclerosis-ESIMS- is described. Three hundred and…”
Get full text

No effect of intravenous immunoglobulins on cytokine-producing lymphocytes in secondary progressive multiple sclerosis by Petereit, H F, Reske, D, Pukrop, R, Maas-Enriquez, M, Japp, G, Jongen, P JH, Kölmel, H W, Merkelbach, S, Hartung, H P, Heiss, W D, Hommes, O R

“…Intravenous immunoglobulins (IVIG) have been effective in reducing multiple sclerosis (MS) disease activity and improving disability scores. However, the…”
Get full text

Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A by Pocoski J, Li N, Ayyagari R,Church N, Maas Enriquez M, Xiang Q, Kelkar S, Du EX, Wu EQ, Xie J

“…Jennifer Pocoski,1 Nanxin Li,2 Rajeev Ayyagari,2 Nikki Church,1 Monika Maas Enriquez,1 Quer Xiang,2 Sneha Kelkar,3 Ella X Du,2 Eric Q Wu,2 Jipan Xie3 1Bayer…”
Get full text

Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial by Engel, W King, Fazekas, F, Lublin, F D, Li, D, Freedman, M S, Hartung, H P, Rieckmann, P, Soelberg Sørensen, P, Maas-Enriquez, M, Sommerauer, B, Hanna, K

Get full text

Peripheral deposition of α 1 ‐protease inhibitor using commercial inhalation devices by Brand, P., Beckmann, H., Maas Enriquez, M., Meyer, T., Müllinger, B., Sommerer, K., Weber, N., Weuthen, T., Scheuch, G.

“…Patients with hereditary α 1 ‐proteinase inhibitor (α 1 ‐PI) deficiency are at risk of developing lung emphysema. To prevent the development of this disease, α…”
Get full text

Peripheral deposition of alpha1-protease inhibitor using commercial inhalation devices by Brand, P, Beckmann, H, Maas Enriquez, M, Meyer, T, Müllinger, B, Sommerer, K, Weber, N, Weuthen, T, Scheuch, G

“…Patients with hereditary alpha1-proteinase inhibitor (alpha1-PI) deficiency are at risk of developing lung emphysema. To prevent the development of this…”
Get full text

NRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS) by FAZEKAS, F, SØRENSEN, P. S, HOMMES, O. R, FILIPPI, M, ROPELE, S, LIN, X, KOELMEL, H. W, FERNANDEZ, O, POZZILLI, C, O'CONNOR, P, ENRIQUEZ, M. Maas

Get full text

Difficulties in controlled inhalation of alpha 1-protease inhibitor by Brand, P, Maas Enriquez, M, Meyer, T, Scheuch, G, Weber, N

“…In this paper a number of studies will be summarized which were designed to improve the inhalation of alpha 1 -protease inhibitor in patients with alpha…”
Get more information